CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function

Thakar, Keyur; Novero, Aileen; Das, Arundhati; Lisinschi, Adriana; Mehta, Bella; Ahmed, Tauseef; Liu, Delong

doi:10.1186/2050-7771-2-12

Cited by 4 publications

(3 citation statements)

References 33 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two such HL patients with severe liver dysfunctions were successfully treated with cyclophosphamide, etoposide, procarbazine and prednisone [14]. Another HL patient who had severe liver dysfunction with hyperbilirubinemia was treated with dexamethasone, high-dose cytarabine, and cisplatin regimen (DHAP) until liver dysfunction disappeared.…”

Section: Liver Dysfunctionsmentioning

confidence: 99%

Liver Involvement in Hodgkin's Lymphoma: Types of Injuries and Therapeutic Implications

Mihăilă

2017

IJPPE

View full text Add to dashboard Cite

Abstract. The hepatocytolysis raises questions on following therapeutic conduct when it occurs during chemotherapy for Hodgkin's lymphoma, expression of its liver toxicity. But the onset of primary liver Hodgkin's lymphoma, including the form manifested by acute liver failure, poses even greater problems, as in the case of occurrence of vanishing bile duct syndrome -expression of a paraneoplastic syndrome, hemophagocytic lymphohistiocytosis, peliosis hepatis or association of lymphoma with infection with hepatitis viruses or human immunodeficiency virus or different autoimmune diseases. This review summarizes the clinical experience acquired on the relationship between Hodgkin's lymphoma and liver, from the point of view of clinical manifestations, used treatments and clinical evolution. Suggestions on the course of treatment in patients with Hodgkin's lymphoma and liver damage have been formulated starting from the metabolism and elimination of chemotherapy drugs and taking into account the clinical experience of published clinical trials and cases. This review is a synthesis of knowledge obtained in this field, during the time, of therapeutic possibilities and limits, and formulates potential future milestones for research.

show abstract

Section: Liver Dysfunctionsmentioning

confidence: 99%

Liver Involvement in Hodgkin's Lymphoma: Types of Injuries and Therapeutic Implications

Mihăilă

2017

IJPPE

View full text Add to dashboard Cite

show abstract

“…Recently, we successfully treated two cases of cHL-associated HLH with rituximab and cyclophosphamide, etoposide, procarbazine, and prednisone (CEPP; cyclophosphamide 600 mg/m 2 on days 1–8, etoposide 70 mg/m 2 on days 1–3; procarbazine 60 mg/m 2 PO, and prednisone 60 mg/m 2 PO daily on days 1–10), a regimen with activity against EBV, cHL, and HLH that has been safely used in the setting of liver failure. [15,16]…”

mentioning

confidence: 99%

“…Notably, CEPP has been shown to be a well-tolerated and effective therapy in non-Hodgkin lymphoma and cHL, even in the setting of marked liver and renal dysfunction. [15,19]…”

mentioning

confidence: 99%